U.S., March 8 -- ClinicalTrials.gov registry received information related to the study (NCT06863480) titled 'Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events' on March 03.
Brief Summary: In this study, tocilizumab-aazg (TYENNE) will be administered to see whether tocilizumab-aazg is safe in patients with a burst brain aneurysm and if it may prevent strokes in patients with a burst brain aneurysm.
Study Start Date: July 01, 2025
Study Type: INTERVENTIONAL
Condition:
Aneurysmal Subarachnoid Hemorrhage
Delayed Cerebral Ischemia
Intervention:
DRUG: tocilizumab-aazg (TYENNE)
A single dose of tocilizumab-aazg (TYENNE) will be administered by intravenous drip.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Universi...